JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 1993; 22:1223-1227
© 1993 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feldman, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feldman, A.

Classification of positive inotropic agents

AM Feldman

Peter Belfer Cardiac Laboratories, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.

Although there is increasing recognition that all inotropic agents are not alike, they continue to be viewed in the generic sense because of the lack of a classification system. Analogous to the classification system proposed for the antiarrhythmic agents over 20 years ago, a classification system is proposed that categorizes inotropic agents according to their mechanisms of action. Agents are classified as those that augment contractility by increasing intracellular levels of cyclic adenosine monophosphate (class I); affect ion channels or pumps (class II); modulate intracellular calcium regulation (class III), and augment contractility through multiple pathways (class IV). This classification system does not suggest that some classes of inotropic agents might be more effective than others nor does it imply that potential beneficial effects are shared by all members of each class of drugs. However, it provides a framework for better understanding of the potential benefits and limitations of the traditional inotropic agents as well as the increasing number of new investigational drugs.


This article has been cited by other articles:


Home page
 Card Surg AdultHome page
E. B. Savage, R. S. Farivar, and E. J. Okum
Cardiac Surgical Physiology
Card. Surg. Adult, January 1, 2008; 3(2008): 51 - 76.
[Full Text]

Home page
 Card Surg AdultHome page
J. Vinten-Johansen, Z.-Q. Zhao, and R. A. Guyton
Cardiac Surgical Physiology
Card. Surg. Adult, January 1, 2003; 2(2003): 53 - 84.
[Full Text]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
M. B. Vroom
Pharmacologic Management of Acute Heart Failure: A Review
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 1998; 2(3): 191 - 203.
[Abstract] [PDF]

Home page
 CirculationHome page
K. W. Mahaffey, T. E. Raya, G. D. Pennock, E. Morkin, and S. Goldman
Left Ventricular Performance and Remodeling in Rabbits After Myocardial Infarction : Effects of a Thyroid Hormone Analogue
Circulation, February 1, 1995; 91(3): 794 - 801.
[Abstract] [Full Text]


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1993 by the American College of Cardiology Foundation.